Information contained on this page is provided by companies via press release distributed through PR Newswire, an independent third-party content provider. PR Newswire, WorldNow and this Station make no warranties or representations in connection therewith.
SOURCE Hannibal Regional Medical Group
HANNIBAL, Mo., March 1, 2013 /PRNewswire-USNewswire/ -- After several years of clinical studies, Allergan, Inc. today announced that the company has received approval from the U.S. Food and Drug Administration (FDA) to market the Natrelle® 410 Highly Cohesive Anatomically Shaped Silicone-Filled Breast Implants for use in breast reconstruction, augmentation and revision surgery. Dr. Schuyler C. Metlis, board certified plastic surgeon with Hannibal Regional Medical Group, is one of only approximately 125 plastic surgeons in the country who have used this implant, after being involved in the clinical study.
"The FDA approval of Natrelle® 410 shaped gel implants provides an important new alternative to traditional round implants for women considering breast augmentation, reconstruction or revision surgery," said David E.I. Pyott, Allergan's Chairman of the Board, President and Chief Executive Officer.
"Due to my participation for the past 7½ years in the study of this superior latest generation cohesive gel implant, I am sure that women will be very pleased with their surgical results," said Dr. Metlis.
The Natrelle® 410 shaped gel implant is designed to mimic the slope of the breast and is filled with a highly cohesive silicone gel, which is intended to enable the implant to hold its shape over time while remaining soft to the touch.
To schedule an appointment with Dr. Metlis to see if you are a candidate for this new product, call 573-629-3500. For more information, visit hannibalregionalmedicalgroup.org.
©2012 PR Newswire. All Rights Reserved.
